(pGlu-Gln)-CCK-8 peptide

(pGlu-Gln)-CCK-8 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Pyr-QDY(SO3H)MGWMDF-NH2

H-pGlu-Gln-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

10

95.12%

C₅₉H₇₅N₁₃O₂₀S₃

1382.49

Synthetic

Powder

(pGlu-Gln)-CCK-8 is a novel cholecystokinin agonist, a synthetic peptide analogue of CCK-8. It acts as a pancreatic beta cell growth factor and anti-apoptotic agent, similar to incretin hormones GLP-1 and GIP. (pGlu-Gln)-CCK-8 stimulates insulin release and inhibits food intake in a concentration-dependent manner. The peptide shows promise for treating obesity and diabetes due to its metabolic stability and in vitro biological activity. (pGlu-Gln)-CCK-8 exerts its effects through CCK1 receptor activation, leading to satiety and reduced food intake.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Irwin N, Pathak V, Flatt PR. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes. 2015 Aug;64(8):2996-3009. doi: 10.2337/db15-0220. Epub 2015 Apr 16. Erratum in: Diabetes. 2016 Apr;65(4):1120. PMID: 25883113.
• Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FPM, Flatt PR. Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes. Diabetologia. 2012 Oct;55(10):2747-2758. doi: 10.1007/s00125-012-2654-6. Epub 2012 Jul 20. PMID: 22814764.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.